Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643885 · ClinicalTrials.gov registry record
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 7,304
- Enrollment target
NCT05643885 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 7,304 participants.
The verdict
NCT05643885 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 7,304 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,304 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2024-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05643885
The ClinicalTrials.gov registry entry for NCT05643885 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05643885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05643885 about?
NCT05643885 is a clinical study titled "A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer". The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause co...
What is the current status of trial NCT05643885?
This trial is currently completed. The enrollment target is 7,304 participants. The study started on 2022-08-31. Estimated completion is 2024-08-30.
Who is sponsoring clinical trial NCT05643885?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.